Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.780
-0.040 (-2.20%)
Oct 7, 2025, 1:50 PM EDT - Market open
Ocugen Revenue
Ocugen had revenue of $1.37M in the quarter ending June 30, 2025, with 20.33% growth. This brings the company's revenue in the last twelve months to $4.75M, down -34.54% year-over-year. In the year 2024, Ocugen had annual revenue of $4.05M, down -32.82%.
Revenue (ttm)
$4.75M
Revenue Growth
-34.54%
P/S Ratio
110.40
Revenue / Employee
$50,042
Employees
95
Market Cap
555.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.05M | -1.98M | -32.82% |
Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
Dec 31, 2022 | 2.49M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 43.00K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OCGN News
- 14 days ago - Ocugen: A Retinal Disease Juggernaut In The Making - Seeking Alpha
- 21 days ago - Ocugen Shares Are Trading Higher Monday: What's Going On? - Benzinga
- 22 days ago - Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - GlobeNewsWire
- 5 weeks ago - Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 - GlobeNewsWire
- 7 weeks ago - Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - GlobeNewsWire
- 7 weeks ago - Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - GlobeNewsWire
- 2 months ago - Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - GlobeNewsWire
- 2 months ago - Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript - Seeking Alpha